secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-062888
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Q3 net loss $19.2M; STRIDE topline results expected December 2023
-----------------------------------------------------------------------

- Net loss of $19.2M ($0.57/sh) vs $13.0M ($0.53/sh) in Q3 2022; R&D expense up to $13.6M.
- Cash, cash equivalents, and short-term investments of $125.6M as of September 30, 2023.
- Topline results from pivotal STRIDE study in adult PMM patients expected in December 2023.
- Repurchased 576,443 shares for $4.4M from vTv Therapeutics in October 2023; shares retired.
- Enrolled 88% of eligible STRIDE patients in open-label extension; 65 patients treated beyond 52 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023062888/0000950170-23-062888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023062888/rphm-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer